Brain metastasis (BM) predominantly occurs in triple-negative (TN) and epidermal growth
factor 2 (HER2)-positive breast cancer (BC) patients, and currently, there is an unmet need …

Background and purpose To analyze outcomes of non-small cell lung cancer (NSCLC)
patients with brain metastases harboring EGFR or ALK mutations and examine for …

Lung cancer (LC) ranks first among all causes of cancer-related death, with non-small cell
lung cancer (NSCLC) taking up 85% of lung cancer cases. Although lncRNA MCM3AP …

Simple Summary In the current era of precision medicine, the management of patients with
brain metastases (BMs) is rapidly evolving. The technical evolution of radiotherapy, now …

This study compared the therapeutic effect of first-line epidermal growth factor receptor
tyrosine kinase inhibitor (EGFR-TKI) with that of EGFR-TKI plus whole brain radiotherapy …

Background As the first-line treatment, afatinib is commonly used in patients with EGFR-
mutated non–small-cell lung cancer (NSCLC). However, dose adjustments are frequently …

Aim. The aim of this study is to evaluate the efficacy and safety of afatinib in the treatment of
non‐small cell lung cancer (NSCLC) patients with brain metastasis based on meta‐analysis …

背景与目的晚期表皮生长因子受体(epidermal growth factor receptor, EGFR)
基因突变的肺腺癌在初诊或治疗过程中脑转移的总发生率高, 局部治疗联合系统性靶向治疗可能 …

Brain metastases are the major cause of life-expectancy shortened for patients with lung
cancer. The prognostic value of EGFR mutation subtypes and survival benefit of EGFR …

Background and objective Advanced epidermal growth factor receptor (EGFR)-mutant lung
adenocarcinoma had a high overall incidence of brain metastasis during the full course, and …